sGC Inhibitors
1 drugsAbout sGC
Soluble guanylate cyclase (sGC) is an enzyme crucial in cardiovascular physiology, regulating vasodilation, inflammation, and fibrosis. Activated by nitric oxide (NO), sGC produces cyclic GMP (cGMP), a second messenger mediating these effects.
sGC is a therapeutic target due to its role in vasodilation. Currently, there is no genetic evidence data available linking sGC to specific diseases.
sGC is targeted by one FDA-approved drug, VERQUVO (Merck), a small molecule used in cardiovascular medicine. VERQUVO was first approved in 2021.
Top sGC Drugs
Merck is the only company with an approved sGC-targeting drug.
High market concentration suggests significant entry barriers; focus on novel mechanisms or indications.
sGC Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets sGC, using small molecule modality.
Explore alternative modalities like biologics to differentiate from existing small molecule approaches.
sGC Clinical Trials 31 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on sGC. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 8 | 7 | 0 | 1 | 100% |
| Phase 2 | 12 | 6 | 0 | 6 | 100% |
| Phase 3 | 2 | 2 | 0 | 0 | 100% |
| Phase 4 | 9 | 2 | 0 | 7 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
sGC Drug Approval Timeline (2021 - 2021)
The first and only sGC-targeting drug, VERQUVO, was approved in 2021.
Recent approval indicates a growing interest in sGC modulation, but market saturation is low.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 18 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on sGC. A trial counts if an approved drug acting on sGC is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.